全文获取类型
收费全文 | 2912篇 |
免费 | 229篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 92篇 |
妇产科学 | 38篇 |
基础医学 | 275篇 |
口腔科学 | 57篇 |
临床医学 | 297篇 |
内科学 | 689篇 |
皮肤病学 | 27篇 |
神经病学 | 112篇 |
特种医学 | 130篇 |
外科学 | 400篇 |
综合类 | 61篇 |
一般理论 | 5篇 |
预防医学 | 155篇 |
眼科学 | 51篇 |
药学 | 287篇 |
中国医学 | 2篇 |
肿瘤学 | 459篇 |
出版年
2022年 | 10篇 |
2021年 | 46篇 |
2020年 | 21篇 |
2019年 | 44篇 |
2018年 | 37篇 |
2017年 | 29篇 |
2016年 | 59篇 |
2015年 | 55篇 |
2014年 | 56篇 |
2013年 | 115篇 |
2012年 | 146篇 |
2011年 | 135篇 |
2010年 | 87篇 |
2009年 | 89篇 |
2008年 | 134篇 |
2007年 | 105篇 |
2006年 | 164篇 |
2005年 | 134篇 |
2004年 | 97篇 |
2003年 | 130篇 |
2002年 | 106篇 |
2001年 | 103篇 |
2000年 | 87篇 |
1999年 | 92篇 |
1998年 | 57篇 |
1997年 | 53篇 |
1996年 | 52篇 |
1995年 | 38篇 |
1994年 | 44篇 |
1993年 | 48篇 |
1992年 | 69篇 |
1991年 | 61篇 |
1990年 | 74篇 |
1989年 | 73篇 |
1988年 | 66篇 |
1987年 | 66篇 |
1986年 | 57篇 |
1985年 | 45篇 |
1984年 | 33篇 |
1983年 | 22篇 |
1982年 | 25篇 |
1981年 | 22篇 |
1980年 | 16篇 |
1979年 | 15篇 |
1978年 | 17篇 |
1977年 | 15篇 |
1976年 | 14篇 |
1975年 | 12篇 |
1974年 | 11篇 |
1970年 | 9篇 |
排序方式: 共有3148条查询结果,搜索用时 15 毫秒
71.
C. Pitart F. Marco T. A. Keating W. W. Nichols J. Vila 《Antimicrobial agents and chemotherapy》2015,59(6):3059-3065
Ceftazidime-avibactam and comparator antibiotics were tested by the broth microdilution method against 200 Enterobacteriaceae and 25 Pseudomonas aeruginosa strains resistant to fluoroquinolones (including strains with the extended-spectrum β-lactamase [ESBL] phenotype and ceftazidime-resistant strains) collected from our institution. The MICs and mechanisms of resistance to fluoroquinolone were also studied. Ninety-nine percent of fluoroquinolone-resistant Enterobacteriaceae strains were inhibited at a ceftazidime-avibactam MIC of ≤4 mg/liter (using the susceptible CLSI breakpoint for ceftazidime alone as a reference). Ceftazidime-avibactam was very active against ESBL Escherichia coli (MIC90 of 0.25 mg/liter), ESBL Klebsiella pneumoniae (MIC90 of 0.5 mg/liter), ceftazidime-resistant AmpC-producing species (MIC90 of 1 mg/liter), non-ESBL E. coli (MIC90 of ≤0.125 mg/liter), non-ESBL K. pneumoniae (MIC90 of 0.25 mg/liter), and ceftazidime-nonresistant AmpC-producing species (MIC90 of ≤0.5 mg/liter). Ninety-six percent of fluoroquinolone-resistant P. aeruginosa strains were inhibited at a ceftazidime-avibactam MIC of ≤8 mg/liter (using the susceptible CLSI breakpoint for ceftazidime alone as a reference), with a MIC90 of 8 mg/liter. Additionally, fluoroquinolone-resistant mutants from each species tested were obtained in vitro from two strains, one susceptible to ceftazidime and the other a β-lactamase producer with a high MIC against ceftazidime but susceptible to ceftazidime-avibactam. Thereby, the impact of fluoroquinolone resistance on the activity of ceftazidime-avibactam could be assessed. The MIC90 values of ceftazidime-avibactam for the fluoroquinolone-resistant mutant strains of Enterobacteriaceae and P. aeruginosa were ≤4 mg/liter and ≤8 mg/liter, respectively. We conclude that the presence of fluoroquinolone resistance does not affect Enterobacteriaceae and P. aeruginosa susceptibility to ceftazidime-avibactam; that is, there is no cross-resistance. 相似文献
72.
73.
The control and eventual elimination of neglected tropical disease (NTD) requires the expansion of interventions such as mass drug administration (MDA), vector control, diagnostic testing, and effective treatment. The purpose of this paper is to present the evidence base for decision-makers on the cost and cost-effectiveness of lymphatic filariasis (LF) and onchocerciasis prevention, treatment, and control. A systematic review of the published literature was conducted. All studies that contained primary or secondary data on costs or cost-effectiveness of prevention and control were considered. A total of 52 papers were included for LF and 24 papers were included for onchocerciasis. Large research gaps exist on the synergies and cost of integrating NTD prevention and control programs, as well as research on the role of health information systems, human resource systems, service delivery, and essential medicines and technology for elimination. The literature available on costs and cost-effectiveness of interventions is also generally older, extremely focal geographically and of limited usefulness for developing estimates of the global economic burden of these diseases and prioritizing among various intervention options. Up to date information on the costs and cost-effectiveness of interventions for LF and onchocerciasis prevention are needed given the vastly expanded funding base for the control and elimination of these diseases. 相似文献
74.
75.
76.
Standardized criteria for diagnosis and response evaluation in chronic lymphocytic leukemia (CLL) are essential to achieve comparability of results and improvement of clinical care. With the increasing range of therapeutic options, the treatment context is important when defining refractory CLL. Refractory CLL has been defined as no response or response lasting ≤ 6 months from last therapy. This subgroup has a very poor outcome, and many trials use this group as an entry point for early drug development. With the intensification of first-line regimens, the proportion of patients with refractory CLL using these criteria decreases. This has immediate consequences for recruitment of patients into trials as well as salvage strategies. Conversely, patients who are not refractory according to the traditional definition but who have suboptimal or short response to intense therapy also have a very poor outcome. In this Perspective, we discuss recent results that may lead to a reassessment of risk categories in CLL focusing on fit patients who are eligible for all treatment options. We cover aspects of the history and biologic basis for refractory CLL and will focus on how emerging data on treatment failure from large trials using chemoimmunotherapy may help to define risk groups in CLL. 相似文献
77.
78.
D. J Keating H. Peiris M. Kyloh S. J. H. Brookes N. J. Spencer 《Neurogastroenterology and motility》2013,25(10):849-853
79.
80.